WEGOVY- semaglutide tablet, DailyMed (2026) Lillys oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity, Lilly (2025) Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes, a randomized clinical trial, JAMA Network Open (2023) Pfizer provides update on oral GLP-1 receptor agonist danuglipron, Pfizer (2025) Oral semaglutide, Clinical Diabetes (2020) Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet (2023) A review of current guidelines for the treatment of obesity, American Journal of Managed Care (2022) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
The NHS recommends staying within the recommended daily allowance (RDA) of 375 mg for adults
Safety Toxicity High doses (10,000 to 16,000 mg/day) of choline have been associated with a fishy body odor, vomiting, salivation, and increased sweating
Inadequate calcium intake is a contributing factor in the development of osteoporosis
